ClinicalTrials.gg

Program

bicalutamide

Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.

Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.

Furthest: phase 4, since Oct 26, 200521 company-led studies, 1 open or runningNext primary completion: Apr 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca130 open or runningphase 4since Oct 26, 2005Oct 16, 2004none ahead
Alessa Therapeutics21 open or runningphase 1since Feb 12, 2020Feb 12, 2020Apr 24, 2027phase 1 · NCT04943536
Kremers Urban Development20 open or runningphase 1since Dec 23, 2009Dec 23, 2009none ahead
Novartis20 open or runningphase 1since Aug 13, 2009Aug 13, 2009none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Sep 8, 2009Sep 8, 2009none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Oct 16, 2004.

  1. Oct 26, 2005Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00255268 · 15 enrolled · Mexico
  2. Dec 28, 2007Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00590213 · 125 enrolled · Turkey
  3. Mar 12, 2008Phase 2 study in GynecomastiaAstraZeneca · NCT00637871
  4. Apr 7, 2008Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00657904 · 3,618 enrolled · United States, Canada
  5. May 2, 20082 phase 3 studies in Prostatic NeoplasmsAstraZeneca · NCT00673205, NCT00672282
  6. Feb 18, 2009Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00846976 · 101 enrolled · United States
  7. Aug 13, 2009Novartis's first studies: 2 phase 1 studies in Prostatic NeoplasmsNew to NovartisNovartis · NCT00960310, NCT00959335
  8. Sep 8, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00973050, NCT00972855
  9. Dec 23, 2009Kremers Urban Development's first study: phase 1 study in BioequivalencyNew to Kremers Urban DevelopmentKremers Urban Development · NCT01039233 · 60 enrolled · Canada
  10. Jan 7, 2010Phase 1 study in HealthyKremers Urban Development · NCT01044706 · 60 enrolled · Canada
  11. Aug 11, 20114 phase 1 studies in HealthyAstraZeneca · NCT01415791, NCT01415778, NCT01416883 and 1 more
  12. Mar 21, 2019Phase 4 study in Advanced Prostate CancerAstraZeneca · NCT03971110 · 9 enrolled · China
  13. Feb 12, 2020Alessa Therapeutics's first study: phase 1 study in Lower Urinary Tract SymptomsNew to Alessa TherapeuticsAlessa Therapeutics · NCT04284761 · 17 enrolled · United States, Australia, New Zealand
  14. Jun 15, 2021Phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536 · 20 enrolled · United States

Ahead

  1. Apr 24, 2027Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04943536Prostate Adenocarcinoma · United States1Active, not recruitingAlessa TherapeuticsApr 24, 202720
NCT04284761Lower Urinary Tract Symptoms · United States, Australia, New Zealand1CompletedAlessa TherapeuticsMay 3, 202317
NCT03971110Advanced Prostate Cancer · China4TerminatedAstraZenecaNov 9, 20229
NCT01416883Healthy1TerminatedAstraZenecaAug 20108
NCT01416870Healthy1TerminatedAstraZenecaNov 2010102
NCT01415791Healthy1CompletedAstraZenecaSep 20118
NCT01415778Healthy1CompletedAstraZenecaNov 201148
NCT01044706Healthy · Canada1CompletedKremers Urban DevelopmentJul 200560
NCT01039233Bioequivalency · Canada1CompletedKremers Urban DevelopmentJun 200560
NCT00973050Healthy · Canada1CompletedTeva Pharmaceutical IndustriesSep 200360
NCT00972855Healthy · Canada1CompletedTeva Pharmaceutical IndustriesSep 200360
NCT00960310Prostatic Neoplasms1CompletedNovartisJun 200636
NCT00959335Prostatic Neoplasms1CompletedNovartisAug 200636
NCT00846976Prostatic Neoplasms · United States3CompletedAstraZenecaJun 2013101
NCT00673205Prostatic Neoplasms · Australia, Austria, Belgium and more3CompletedAstraZenecaAug 20083,588
NCT00672282Prostatic Neoplasms · Denmark, Finland, Norway and more3CompletedAstraZeneca1,218
NCT00657904Prostatic Neoplasms · United States, Canada3CompletedAstraZenecaJul 20083,618
NCT00637871Gynecomastia2CompletedAstraZenecaJun 2005
NCT00590213Prostatic Neoplasms · Turkey4CompletedAstraZeneca125
NCT00255268Prostatic Neoplasms · Mexico4WithdrawnAstraZeneca15
NCT00094328Puberty, Precocious · United States, Canada, France and more2CompletedAstraZenecaMay 22, 200814

How it is read

Names in the registry

  • “Bicalutamide”, 9 entries
  • “ICI176,334-1”, 4 entries
  • “bicalutamide”, 2 entries
  • “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
  • “Casodex 80 mg tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.